MedPath

Efficacy of MASPORT in Blepharospasm

Phase 3
Recruiting
Conditions
Benign Essential Blepharospasm (BEB).
Blepharospasm
G24.5
Registration Number
IRCT20240216061023N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
19
Inclusion Criteria

Clinically diagnosed with BEB
Without prior BTX-A injection in the previous 6 month
History of previous eyelid surgery

Exclusion Criteria

pregnancy or lactation
secondary causes of Blepharospasm
History of disorders of the neuromuscular junction like myasthenia gravis, Eaton-Lambert Syndrome, and psychological instability
prescription of antispastic, muscle relaxants or medications affecting neuromuscular junction transmission such as aminoglycosides

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Advance in the severity and frequency grades of spasms (more than at least one grade improvement in severity score. Timepoint: Four weeks post-injection phase. Method of measurement: Based on Severity and Frequency Spasm Score.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath